File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Scopus: eid_2-s2.0-0026776311
- PMID: 1623907
- WOS: WOS:A1992JD50800016
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Dipyridamole increases human red blood cell deformability
Title | Dipyridamole increases human red blood cell deformability |
---|---|
Authors | |
Keywords | Dipyridamole haemodialysis peripheral vascular disease Red cell deformability renal failure |
Issue Date | 1992 |
Publisher | Springer Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/00228/index.htm |
Citation | European Journal Of Clinical Pharmacology, 1992, v. 42 n. 6, p. 651-654 How to Cite? |
Abstract | An automated filtration technique has been used to investigate the effect of dipyridamole (DP) on red blood cell deformability in patients identified as having rigid red cells. They were patients on haemodialysis (HD) for chronic renal failure (n = 18), patients with peripheral vascular disease (PVD, n = 23) and controls (hospital out-patients, n = 33). Leucocytes and platelets were removed from heparinised blood by filtration through Imugard wool. Washed red cell suspensions in buffer at 5% haematocrit, without or with 5 μM DP, were filtered through Nuclepore Hemafil Membranes with 4.7 μm pores. The initial steady state relative filtration pressure (iRFP) was used to assess cell deformability. A low iRFP value reflects increased deformability and vice versa. The mean iRFP values were 0.33, 0.393 and 0.403 for controls, PVD and HD patients respectively, indicating that the red cells in the two groups of patients were significantly more rigid. DP reduced the iRFP to 0.266, 0.278 and 0.263 for controls, PVD and HD patients respectively. The results suggest that DP may be beneficial when red cell rigidity contributes to impaired microvascular perfusion. |
Persistent Identifier | http://hdl.handle.net/10722/161955 |
ISSN | 2023 Impact Factor: 2.4 2023 SCImago Journal Rankings: 0.727 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Saniabadi, AR | en_US |
dc.contributor.author | Fisher, TC | en_US |
dc.contributor.author | Lau, CS | en_US |
dc.contributor.author | Bridges, A | en_US |
dc.contributor.author | Taylor, J | en_US |
dc.contributor.author | Belch, J | en_US |
dc.contributor.author | Forbes, CD | en_US |
dc.date.accessioned | 2012-09-05T05:16:17Z | - |
dc.date.available | 2012-09-05T05:16:17Z | - |
dc.date.issued | 1992 | en_US |
dc.identifier.citation | European Journal Of Clinical Pharmacology, 1992, v. 42 n. 6, p. 651-654 | en_US |
dc.identifier.issn | 0031-6970 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/161955 | - |
dc.description.abstract | An automated filtration technique has been used to investigate the effect of dipyridamole (DP) on red blood cell deformability in patients identified as having rigid red cells. They were patients on haemodialysis (HD) for chronic renal failure (n = 18), patients with peripheral vascular disease (PVD, n = 23) and controls (hospital out-patients, n = 33). Leucocytes and platelets were removed from heparinised blood by filtration through Imugard wool. Washed red cell suspensions in buffer at 5% haematocrit, without or with 5 μM DP, were filtered through Nuclepore Hemafil Membranes with 4.7 μm pores. The initial steady state relative filtration pressure (iRFP) was used to assess cell deformability. A low iRFP value reflects increased deformability and vice versa. The mean iRFP values were 0.33, 0.393 and 0.403 for controls, PVD and HD patients respectively, indicating that the red cells in the two groups of patients were significantly more rigid. DP reduced the iRFP to 0.266, 0.278 and 0.263 for controls, PVD and HD patients respectively. The results suggest that DP may be beneficial when red cell rigidity contributes to impaired microvascular perfusion. | en_US |
dc.language | eng | en_US |
dc.publisher | Springer Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/00228/index.htm | en_US |
dc.relation.ispartof | European Journal of Clinical Pharmacology | en_US |
dc.subject | Dipyridamole | - |
dc.subject | haemodialysis | - |
dc.subject | peripheral vascular disease | - |
dc.subject | Red cell deformability | - |
dc.subject | renal failure | - |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Aged | en_US |
dc.subject.mesh | Dipyridamole - Pharmacology | en_US |
dc.subject.mesh | Erythrocyte Deformability - Drug Effects | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Kidney Failure, Chronic - Blood | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Middle Aged | en_US |
dc.subject.mesh | Peripheral Vascular Diseases - Blood | en_US |
dc.subject.mesh | Renal Dialysis | en_US |
dc.title | Dipyridamole increases human red blood cell deformability | en_US |
dc.type | Article | en_US |
dc.identifier.email | Lau, CS:cslau@hku.hk | en_US |
dc.identifier.authority | Lau, CS=rp01348 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.pmid | 1623907 | - |
dc.identifier.scopus | eid_2-s2.0-0026776311 | en_US |
dc.identifier.volume | 42 | en_US |
dc.identifier.issue | 6 | en_US |
dc.identifier.spage | 651 | en_US |
dc.identifier.epage | 654 | en_US |
dc.identifier.isi | WOS:A1992JD50800016 | - |
dc.publisher.place | Germany | en_US |
dc.identifier.scopusauthorid | Saniabadi, AR=18936909200 | en_US |
dc.identifier.scopusauthorid | Fisher, TC=7202246856 | en_US |
dc.identifier.scopusauthorid | Lau, CS=14035682100 | en_US |
dc.identifier.scopusauthorid | Bridges, A=8903578700 | en_US |
dc.identifier.scopusauthorid | Taylor, J=7405402501 | en_US |
dc.identifier.scopusauthorid | Belch, J=7101752869 | en_US |
dc.identifier.scopusauthorid | Forbes, CD=7103200092 | en_US |
dc.identifier.issnl | 0031-6970 | - |